Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, et al.

Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985; 2:407–410.

2. Rafatpanah H, Hedayati-Moghaddam MR, Fathimoghadam F, Bidkhori HR, Shamsian SK, Ahmadi S

, et al.

High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey. J Clin Virol 2011; 52:172-176.

3. Montanheiro PA, Oliveira AC, Posada-Vergara MP, Milagres AC, Tauil C, Marchiori PE,

et al.

Human T-cell lymphotropic virus type I (HTLV-I) proviral DNA viral load among asymptomatic patients and patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. Braz J Med Biol Res 2005; 38:1643–1647.

4. Best I, Adaui V, Verdonck K, Gonzalez E, Tipismana M, Clark D,

et al.

Proviral load and immune markers associated with human T-lymphotropic virus type 1 (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Peru. Clin Exp Immunol 2006; 146:226–233.

5. Kira J, Koyanagi Y, Yamada T, Itoyama Y, Goto I, Yamamoto N,

et al.

Increased HTLV-I proviral DNA in HTLV-I-associated myelopathy: a quantitative polymerase chain reaction study. Ann Neurol 1991; 29:194–201.

6. Cabral F, Arruda LB, de Araújo ML, Montanheiro P, Smid J, de Oliveira AC,

et al.

Detection of human T-cell lymphotropic virus type 1 in plasma samples. Virus Res 2012; 163:87-90.

7. Gürcan HM, Ahmed AR. Efficacy of various intravenous immunoglobulin therapy protocols in autoimmune and chronic inflammatory disorders. Ann Pharmacother ;2007 823–41:812.

8. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV.Intravenous immunoglobulin for infectious diseases: Back to the pre-antibiotic and passive prophylaxis era? Trends Pharmacol Sci 2004; 25:306–310.

9. de Gracia J, Vendrell M, Alvarez A, Pallisa E, Rodrigo MJ, de la Rosa D,

et al.

Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol 2004; 4:745–753.

10. Bayrakci B, Ersoy F, Sanal O, Kiliç S, Metin A, Tezcan I. The efficacy of immunoglobulin replacement therapy in the long-term follow-up of the B-cell deficiencies (XLA, HIM, CVID). Turk J Pediatr 2005; 47:239–246.

11. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003; 139:1051–1059.

12. Masson PL. Elimination of infectious antigens and increase of IgG catabolism as possible modes of action of IVIg. J Autoimmun 1993; 6:683–689.

13. Lejtenyi D, Mazer B. Consistency of protective antibody levels across lots of intravenous immunoglobulin preparations. J Allergy Clin Immunol 2008; 121:254-25.

14. Razvi S, Schneider L, Jonas MM, Cunningham-Rundles C.Outcome of intravenous immunoglobulin-transmitted hepatitis C virus infection in primary immunodeficiency. Clin Immunol 2001; 101:284-288.

15. Allen HJ, Seeff L. Recovery persistence and sequelae in hepatitis C virus infection: A perspective on long-term outcome. Semin Liver Dis 2000; 20:17–35.

16. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N,

et al

. The natural history of hepatitis C virus infection: Host, visual and environmental factors. JAMA 20002; 84:450–456.

17. Stephan W, Prince AM, Brotman B. Modulation of hepatitis B infection by intravenous application of an immunoglobulin preparation that contains antibodies to hepatitis B e and core antigens but not to hepatitis B surface antigen. J Virol 1984;

231

51:420-424.

18. Brémard-Oury C, Couroucé AM, Badillet M, Huchet J, Chapelle A, Bierling P,

et al.

Prevalence of anti-HIV antibodies in immunoglobulins recipients. Presse Med. 1987 ; 16:2013-2018.

19. Bjøro K, Frøland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminatedimmune globulin. N Engl J Med 1994; 331:1607–1611.

20. Bresee JS, Mast EE, Coleman PJ, Baron MJ, Schonberger LB, Alter MJ,

et al.

Hepatitis C virus infection associated with administration of intravenous immune globulinA cohort study. JAMA 1996; 276:1563–1567.

21. Jonas MM, Baron MJ, Bresee JS, Schneider LC. Clinical and virologic features of hepatitis C virus infection associated with intravenous immunoglobulin. Pediatrics. 1996; 98:211-215.

22. Yap PL, McOmish F, Webster AD, Hammarstrom L, Smith CI, Bjorkander J. Hepatitis C virus transmission by intravenous immunoglobulin. J Hepatol 1994; 21:455-460.

23. Sinclair J. Intravenous Immunoglobulin (IVIG) Therapy – Practical Aspects. Starship Children’s Health Clinical Guideline. 2007; 23:1-3.

24. Healey CJ, Sabharwal NK, Daub J, Davidson F, Yap PL, Fleming KA. Outbreak of acute hepatitis C following the use of anti-hepatitis C virus--screened intravenous immunoglobulin therapy. Gastroenterology 1996; 110:1120-1126.

25. Rossi G, Tucci A, Cariani E, Ravaggi A, Rossini A, Radaeli E. Outbreak of hepatitis C virus infection in patients with hematologic disorders treated with intravenous immunoglobulins: different prognosis according to the immune status. Blood 1997; 90:1309- 1314.

26. Bresee JS, Mast EE, Coleman PJ, Baron M, Schonberger L, Alter J,

et al.

Hepatitis C virus infection associated with administration of intravenous immune globulin. JAMA 1996; 276:1563–1567.